GlassScriptPhysician profile
Gustavo D Rivera
NPI 1154573830
$16,606.29
in general payments reported to CMS, 2019-2025
34 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $1,347 · 2021: $1,759 · 2022: $2,030 · 2023: $1,651 · 2024: $6,731 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,182 · Honoraria: $3,870 · Travel and Lodging: $1,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,181.60 |
| Honoraria | $3,870.00 |
| Travel and Lodging | $1,075.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $5,539.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $2,925.68 | 2021-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,210.28 | 2019-2025 | Gattex, Entyvio, Eohilia |
| Fujifilm Healthcare Americas Corporation | $1,191.43 | 2020-2023 | Fujifilm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,033.82 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $857.41 | 2019-2025 | Simponi, Simponi Aria, Stelara |
| Celgene Corporation | $528.64 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $437.13 | 2019-2025 | Ocaliva |
| Pfizer INC. | $365.67 | 2019-2025 | |
| Boston Scientific Corporation | $337.89 | 2020-2025 | Axonics, Resolution 360 Clip, Resolution 360 Ultra Clip |
| Axonics, INC. | $259.81 | 2023-2024 | Axonics |
| Janssen Scientific Affairs, LLC | $249.96 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $179.29 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $159.73 | 2019-2024 | Dificid, Zinplava |
| Phathom Pharmaceuticals, INC. | $156.24 | 2023-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $130.13 | 2024-2025 | Ibsrela |
| Genentech, INC. | $127.33 | 2019 | |
| Gilead Sciences, INC. | $118.76 | 2019 | |
| Braintree Laboratories, INC. | $114.44 | 2021-2025 | Suflave, Sutab |
| Shire North American Group INC | $106.18 | 2019 | |
| Shionogi INC | $96.59 | 2019-2020 | |
| Redhill Biopharma INC. | $92.37 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Ipsen Biopharmaceuticals, INC | $71.57 | 2024 | Iqirvo |
| Vivus LLC | $55.59 | 2021-2025 | Pancreaze |
| Regeneron Healthcare Solutions, INC. | $46.53 | 2025 | Dupixent |
| Exact Sciences Corporation | $42.46 | 2023-2025 | Cologuard Collection Kit |
| Octapharma USA, INC. | $30.90 | 2024 | Balfaxar |
| Janssen Pharmaceuticals, INC | $29.92 | 2025 | Symtuza |
| Alfasigma USA, INC. | $27.59 | 2020 | |
| Biocon Biologics INC | $25.37 | 2025 | Yesintek |
| Ferring Pharmaceuticals INC. | $16.81 | 2023 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $16.35 | 2022 | |
| Lilly USA, LLC | $14.07 | 2024 | Omvoh |
| Dova Pharmaceuticals | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gustavo Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.